Summary of Consolidated Financial Results for the Three Months Ended June 30, 2023 (Based on Japanese GAAP)

August 10, 2023

Company name:

TOWA PHARMACEUTICAL CO., LTD.

Stock exchange listing:

Tokyo

Stock code:

4553

URL

https://www.towayakuhin.co.jp/

Representative:

President and Representative Director

Itsuro Yoshida

Inquiries:

Director

Masao Tanaka

TEL 06-6900-9102

Scheduled date to file Quarterly Securities Report:

August 10, 2023

Scheduled date to commence dividend payments:

-

Preparation of supplementary material on quarterly financial results:

Yes

Holding of quarterly financial results meeting:

Yes

(for analysts and institutional investors)

(Amounts less than one million yen are rounded down)

1. Consolidated financial results for the three months ended June 30, 2023 (from April 1, 2023 to June 30, 2023)

(1) Consolidated operating results (cumulative)

Percentages indicate year-on-year changes

Net sales

Operating profit

Ordinary profit

Profit attributable to

owners of parent

Millions of yen

%

Millions of yen

%

Millions of yen

%

Millions of yen

%

Three months ended June 30, 2023

54,548

20.2

4,096

123.1

6,959

181.8

4,750

245.8

Three months ended June 30, 2022

45,372

5.7

1,836

(69.8)

2,469

(68.0)

1,373

(74.1)

Earnings per share

Diluted earnings per share

Yen

Yen

Three months ended June 30, 2023

96.51

-

Three months ended June 30, 2022

27.91

27.28

(2) Consolidated financial position

Total assets

Net assets

Equity ratio

Millions of yen

Millions of yen

%

As of June 30, 2023

394,170

143,997

36.5

As of March 31, 2023

371,347

136,894

36.9

2. Cash dividends

Annual dividends per share

1st quarter-end

2nd quarter-end

3rd quarter-end

Fiscal year-end

Total

Yen

Yen

Yen

Yen

Yen

Year ended March 31, 2023

-

30.00

-

30.00

60.00

Year ending March 31, 2024

-

Year ending March 31, 2024 (Forecast)

30.00

-

30.00

60.00

3. Forecast of consolidated financial results for the year ending March 31, 2024 (from April 1, 2023 to March 31, 2024)

Percentages indicate year-on-year changes

Net sales

Operating profit

Ordinary profit

Profit attributable to

Earnings per share

owners of parent

Millions of yen

%

Millions of yen

%

Millions of yen

%

Millions of yen

%

Yen

Six months ending

104,600

-

5,800

-

5,600

-

3,400

-

69.08

September 30, 2023

Full year

216,300

-

11,800

-

11,500

-

6,900

-

140.18

Notes: 1. Changes on the latest forecast: No

2. The fiscal period ended March 31, 2023 represents a transitional period for the change in the fiscal period for nine consolidated subsidiaries, scoped 15-month period from January 1, 2022-March 31, 2023. Due to this method of presentation, year-on-year percentage change data is not provided.

1

4. Notes

(1)

Changes in significant subsidiaries during the three months ended June 30, 2023

No

(changes in specified subsidiaries resulting in the change in scope of consolidation):

(2)

Application of special accounting methods for preparing quarterly consolidated financial statements:

No

(3)

Changes in accounting policies, changes in accounting estimates, and restatement of prior period financial statements

Changes in accounting policies due to revisions to accounting standards and other regulations:

No

Changes in accounting policies due to other reasons:

No

Changes in accounting estimates:

No

Restatement of prior period financial statements:

No

(4)

Number of issued shares (common shares)

Total number of issued shares at the end of the period (including treasury shares)

As of June 30, 2023

51,516,000

shares

As of March 31, 2023

51,516,000

shares

Number of treasury shares at the end of the period

As of June 30, 2023

2,294,167

shares

As of March 31, 2023

2,294,167

shares

Average number of shares during the period (cumulative from the beginning of the fiscal year)

Three months ended June 30, 2023

49,221,833

shares

Three months ended June 30, 2022

49,221,899

shares

2

Quarterly consolidated financial statements

Consolidated balance sheets

(Millions of yen)

As of March 31, 2023

As of June 30, 2023

Assets

Current assets

Cash and deposits

24,257

30,817

Notes and accounts receivable - trade

46,795

51,254

Electronically recorded monetary claims - operating

7,777

8,513

Merchandise and finished goods

44,457

47,043

Work in process

13,906

14,712

Raw materials and supplies

34,564

35,778

Other

11,413

13,506

Allowance for doubtful accounts

(180)

(53)

Total current assets

182,990

201,571

Non-current assets

Property, plant and equipment

Buildings and structures, net

56,190

55,783

Machinery, equipment and vehicles, net

18,966

18,160

Land

17,039

17,213

Construction in progress

31,155

37,078

Other, net

3,652

3,804

Total property, plant and equipment

127,004

132,040

Intangible assets

Goodwill

34,613

34,049

Other

18,332

18,380

Total intangible assets

52,945

52,430

Investments and other assets

Investment securities

676

704

Other

8,542

8,242

Allowance for doubtful accounts

(812)

(819)

Total investments and other assets

8,407

8,127

Total non-current assets

188,357

192,598

Total assets

371,347

394,170

3

(Millions of yen)

As of March 31, 2023

As of June 30, 2023

Liabilities

Current liabilities

Notes and accounts payable - trade

17,272

18,272

Electronically recorded obligations - operating

18,798

10,410

Short-term borrowings

3,677

3,921

Current portion of long-term borrowings

7,527

9,302

Income taxes payable

1,190

2,136

Provisions

117

82

Other

29,944

32,622

Total current liabilities

78,529

76,747

Non-current liabilities

Long-term borrowings

150,314

167,829

Retirement benefit liability

322

303

Other

5,287

5,291

Total non-current liabilities

155,923

173,424

Total liabilities

234,453

250,172

Net assets

Shareholders' equity

Share capital

4,717

4,717

Capital surplus

7,837

7,837

Retained earnings

121,232

124,506

Treasury shares

(5,608)

(5,608)

Total shareholders' equity

128,179

131,453

Accumulated other comprehensive income

Valuation difference on available-for-sale securities

106

123

Foreign currency translation adjustment

8,608

12,420

Total accumulated other comprehensive income

8,715

12,543

Total net assets

136,894

143,997

Total liabilities and net assets

371,347

394,170

4

Consolidated statements of income (cumulative) and consolidated statements of comprehensive income (cumulative)

Consolidated statements of income (cumulative)

(Millions of yen)

Three months ended

Three months ended

June 30, 2022

June 30, 2023

Net sales

45,372

54,548

Cost of sales

28,885

34,539

Gross profit

16,486

20,008

Selling, general and administrative expenses

14,650

15,912

Operating profit

1,836

4,096

Non-operating income

Interest income

2

7

Dividend income

2

2

Foreign exchange gains

31

104

Subsidy income

24

29

Gain on valuation of derivatives

621

2,705

Other

92

223

Total non-operating income

774

3,073

Non-operating expenses

Interest expenses

97

192

Other

44

16

Total non-operating expenses

141

209

Ordinary profit

2,469

6,959

Extraordinary income

Gain on sale of non-current assets

-

189

Other

0

2

Total extraordinary income

0

192

Extraordinary losses

Loss on disposal of non-current assets

0

11

Total extraordinary losses

0

11

Profit before income taxes

2,469

7,140

Income taxes

1,095

2,390

Profit

1,373

4,750

Profit attributable to owners of parent

1,373

4,750

5

Attachments

  • Original Link
  • Original Document
  • Permalink

Disclaimer

TOWA Pharmaceutical Co. Ltd. published this content on 10 August 2023 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 10 August 2023 06:22:16 UTC.